TTrialPathMatch Me to Trials
← Back to trials
RecruitingChronic Kidney Disease

A Study to Investigate Safety, Tolerability, PK, and PD of AZD4248 in Healthy Participants, Participants With CKD and Type 2 Diabetes, Assess Home Measurements of Creatinine in a Non-Interventional Cohort, and Assess the Effect of AZD4248 on the PK of Midazolam and Metformin in Healthy Participants

Eligible age

18–75 yrs

Accepts

All genders

Locations

5 states

Healthy volunteers

Yes

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This study will evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses (SAD) and multiple ascending doses (MAD) of AZD4248 administered as an oral solution and intravenous (IV) infusion. Additionally, the study investigates the non-interventional feasibility of home measurement of serum creatinine in participants with diabetic kidney disease (DKD), and the effect of multiple doses of AZD4248 on the PK of oral midazolam and metformin.

Sponsor: AstraZeneca

Where it's recruiting

California

Glendale

Illinois

Chicago

Michigan

Ann Arbor

Minnesota

Saint Paul

Texas

San Antonio

Source: ClinicalTrials.gov · NCT07024823 · last updated 2026-11-12

A Study to Investigate Safety, Tolerability, PK, and PD of AZD4248 in · TrialPath